The effectiveness of vedolizumab to TNF antagonist therapy was assessed for both CD and UC patients, included in a multicentre consortium. Both studies found that vedolizumab-treated patients had higher rates of clinical remission, steroid-free remission, and endoscopic healing than TNF antagonist-treated patients [15,16].
These results were obtained after accounting for measurable disease- and patient-specific characteristics (which may affect biological effectiveness). Researchers performed a propensity score matching (1:1) accounting for age, sex, and prior disease-related hospitalisation within the previous year. Other factors matched were stricturing or penetrating disease complication history, prior bowel surgery, disease severity, steroid refractoriness or dependence, and prior TNF antagonist failure.
Treatment response was categorised using the Physician Global Assessment. Cumulative rates of clinical remission (complete resolution of dise...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Comparative effectiveness of vedolizumab and ustekinumab in CD Next Article
Integration of “omics” and potential for clinical practice »